IP Library Granted Patent US 7,319,094
Granted Patent B2
US 7,319,094 · App. 10/910,173 · Granted Jan 15, 2008

Increased and sustained in vivo gene expression using a nucleic acid, histone and amphipathic compound composition

Assignee: Rhode Island Hospital
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,319,094
App. No.
10/910,173
Granted
Jan 15, 2008
Kind
B2
Abstract

The invention features a non-transgenic model of Alzheimer's Disease, method for inducing prolonged in vivo gene expression in a mammal, and methods of inhibiting Alzheimer's Disease-associated neuronal cell death.

Claims (17)

1. A method for inducing increasing and sustained levels of in vivo gene expression of an exogenous nucleic acid in a mammal over a prolonged period of time, comprising contacting a non-muscular tissue of said mammal with a composition comprising said exogenous nucleic acid, a histone, and an amphipathic compound, wherein increasing and sustained levels of gene expression of said exogenous nucleic acid is detected in said mammal for at least one week after contacting said tissue with said composition.

2. The method of claim 1 , wherein said tissue is neuronal tissue.

3. The method of claim 1 , wherein said tissue is a central nervous system (CNS) tissue.

4. The method of claim 1 , wherein said tissue comprises a post-mitotic neuronal cell.

5. The method of claim 1 , wherein said tissue comprises a cortical neuronal cell.

6. The method of claim 1 , wherein said tissue comprises a hippocampal neuronal cell, a glial cell, or a vascular endothelial cell.

7. The method of claim 1 , wherein increasing and sustained levels of gene expression in said tissue is detected in vivo for at least two weeks after contacting said tissue with said composition.

8. The method of claim 1 , wherein increasing and sustained levels of gene expression in said tissue is detected in vivo for at least four weeks after contacting said tissue with said composition.

9. The method of claim 1 , wherein increasing and sustained levels of gene expression in said tissue is detected in vivo for at least eight weeks after contacting said tissue with said composition.

10. The method of claim 1 , wherein said composition is in the form of a liposome.

11. The method of claim 10 , wherein said liposome is neutral or cationic.

12. The method of claim 10 , wherein said lipsome is anionic.

13. The method of claim 1 , wherein said histone is selected from the group consisting of H1, H2A, H2B, H3, and H4.

14. The method of claim 1 , wherein said composition further comprises a nuclear localizing signal.

15. The method of claim 1 wherein the amphipathic compound is a non-natural polyamine having a hydrophobic moiety, wherein said hydrophobic moiety is selected from the group consisting of a C6-C24 alkane, C6-C24 alkene, sterol, steroid, lipid, fatty acid, and hydrophobic hormone.

16. The method of claim 1 , wherein said nucleic acid is an AD7c-NTP antisense molecule or a nitric oxide synthase III antisense molecule.

17. The method of claim 16 , wherein said nucleic acid comprises a sequence complementary to the nucleotide sequence of SEQ ID NO:1.

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 20, 2013
From: RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029839/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2004
From: WANDS, JACK R.; DE LA MONTE, SUZANNE M.
To: RHODE ISLAND HOSPITAL, A LIFESPAN PARTNER
Reel/Frame 015659/0853 →
Continuity (2)
Continuation 0987296800 · Jun 1, 2001
Related Publication 20050090441A1 · Apr 28, 2005